Stock Ratings / Health Care / ZYME / insiders

GENB (61) SRPT (35) SLS (35) TRVI (39) ⌘ Pro Terminal →

Zymeworks Inc. (ZYME) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$28.71 -0.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.62

Zymeworks Inc. (ZYME) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.02B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $28.62 (-0.31%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZYME)Realized 20D OHLCV Swing Band: ±8.8%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY ZYME SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (30% of score)

Altman Z-Score 11.85 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$25.79-2.9% Next Q

Q2 (-2Q)

Grade D$25.03+12.7% Next Q

Q3 (-1Q)

Grade D$28.22+1.7% Next Q

Current

Grade D$28.71-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZYME Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZYME currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.30) and Max Pain ($30.15) forces dealer call-delta covering toward $32.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZYME• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZYME Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ZYME Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ZYME)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ZYME. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZYME)

✓Walkthrough of ZYME's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZYME // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.25%▲ ASCENDING CHANNEL

2026-10-30O $28.81H $29.01L $28.26C $28.71VOL 2.88M

RES: $34.33SUP: $25.32SMA50: $27.30SMA200: $25.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZYME Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZYME Butterfly Map → + Track ZYME →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +38.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZYME today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZYME. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZYME today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZYME)

Health Care Rank #404 of 1016 ⚔️ GENB vs ZYME Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZYME vs. GENB, SRPT, SLS, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zymeworks Inc. (ZYME) ranks #404 by composite RQD confidence (47/100, grade D) and #263 by equity capitalization ($2.02B). Within this direct 5-issuer industry benchmark cohort, ZYME leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with ZYME at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZYME ACTIVE Zymeworks Inc.	D	47/100	—	—	-32.2%	-0.66%	$2.02B	Benchmark Subject
GENB Generate Biomedicines Inc.	C-	61/100	—	—	—	+2.54%	$2.02B	/genb-vs-zyme →
SRPT Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-0.47%	$2.03B	/srpt-vs-zyme →
SLS SELLAS Life Sciences Group Inc.	D-	35/100	—	—	-21.8%	-2.17%	$2.05B	/sls-vs-zyme →
TRVI Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-zyme →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001937653

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zymeworks Inc. (ZYME) reported GAAP revenue of $106.0M (+38.9% vs. FY2024 revenue of $76.3M , and +39.4% cumulative change since FY2023) , GAAP net income of -$81.1M, operating cash flow of -$33.0M, and free cash flow of -$34.5M (+69.2% YoY). On the balance sheet, ZYME closed FY2025 with $346.5M in total assets against $0 in total debt (Altman Z-Score: 11.85, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$106.0M	-$81.1M	-$33.0M	-$34.5M	$346.5M	—
FY2024 (FY)	2024-12-31	$76.3M	-$122.7M	-$110.1M	-$112.0M	$463.1M	—
FY2023 (FY)	2023-12-31	$76.0M	-$118.7M	-$118.3M	-$118.3M	—	—

3. ZYME Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZYME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Zymeworks Inc. (NASDAQ: ZYME) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $28.71 (-0.66% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZYME ranks #404 in composite RQD confidence.

How does ZYME compare to GENB and SRPT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYME carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.2%. By comparison, GENB (Generate Biomedicines Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.02B) and SRPT (Sarepta Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, ZYME leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZYME?

Per ZYME's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001937653), Zymeworks Inc. generated $106.0M in revenue (+38.9% YoY), -$81.1M in net income, and -$34.5M in free cash flow against $346.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZYME trading relative to its 50-day, 200-day, and 52-week technical levels?

ZYME last traded at $28.71 (-0.66% on volume of 806,250 shares), positioning the stock +5.16% above its 50-day simple moving average ($27.30) and +13.84% above its 200-day simple moving average ($25.22). Across its 52-week range of $16.00 to $31.34, ZYME sits at the 82.9% percentile with a 14-day RSI of 60.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.8% ($26.18 to $31.24).

ZYME Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ZYME insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ZYME leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ZYME RQD Cockpit ZYME 12M Forecast ZYME Earnings & Move ZYME Dividends & DRIP ZYME Insiders & 13F ZYME Whale Options ZYME Profit Sankey ZYME News & Why